Market Desk (health): The study on Nitric Oxide Nasal Spray (NONS) was conducted by Mumbai-based pharmaceutical company Glenmark in 306 vaccinated and unvaccinated adults with symptomatic mild COVID-19 across 20 clinical sites in India.
A nasal spray administered in high-risk adult COVID-19 patients reduced viral load by 94% within 24 hours and 99% in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.
According to the company, the NONS is designed to kill the virus. It primarily acts on the airways. When it is sprayed on mucus, it creates a physical and chemical barrier against the virus. This spray also prevents from spreading into the lungs.
A total of 306 patients were surveyed. They include people from both vaccinated and unvaccinated groups. The study was carried out during the period of excesses of 2 forms, Delta and Omicron.
The company’s chiefs, told the press that the powerful double-blind trial proved the significant effectiveness of NONS. He hopes that this drug is going to play a big role in fighting the epidemic in the future.
This spray called Fabispray is supposed to come in the market. Glenmark has already received approval from the Drugs Controller General of India for the manufacture and marketing of this spray.